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SUMMARY
The presumptive treatment of parasitosis among immigrants with albendazole has been shown to
save both money and lives, primarily via a reduction in the burden of Strongyloides stercoralis.
Ivermectin is more effective than albendazole, but is also more expensive. This coupled with
confusion surrounding the cost-effectiveness of guiding therapy based on eosinophil counts has
led to disparate practices. We used the newly arrived year 2000 immigrant population as a
hypothetical cohort in a decision analysis model to examine the cost-effectiveness of various
interventions to reduce parasitosis among immigrants. When the prevalence of S. stercoralis is
greater than 2%, the incremental cost-effectiveness ratios of all presumptive treatment strategies
were similar. Ivermectin is associated with an incremental cost-effectiveness ratio of $1700 per
QALY gained for treatment with 12 mg ivermectin relative to 5 days of albendazole when the
prevalence is 10%. Any presumptive treatment strategy is cost-effective when compared with
most common medical interventions.
INTRODUCTION
The worldwide burden of intestinal parasitic disease
exceeds 3 billion persons [1]. In 2000, approximately
28.4 million foreign-born persons resided in the
United States, with most originating from countries
where intestinal parasites are endemic [2].When evalu-
ating new immigrants for parasitic infections, phys-
icians may choose watchful waiting, use eosinophilia
as a method to identify high-risk patients, screen for
parasitosis using one or more stool examinations,
or treat presumptively. Factors to consider when
deciding among these options include the fact that
intestinal parasites are common in new immigrant
populations, anti-parasitic agents are effective, safe,
and well tolerated, and stool examinations for para-
sites are labour intensive, costly, and highly insensi-
tive at identifying infection [3, 4].
Among intestinal parasites that are common in new
immigrant populations, S. stercoralis results in the
greatest medical costs, morbidity, and loss of life [4].
This parasite is capable of autoinfection, a phenom-
enon in which the parasite completes its entire life-
cycle within the host, thus leading to multiple
generations of new organisms and persistent infection
for decades [5, 6]. In contrast, most parasites have a
more limited lifespan or rarely result in serious illness
or death. While the majority of persons infected with
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S. stercoralis either remain asymptomatic or develop
mild illness, those who subsequently become im-
munocompromised are at high risk of developing
hyperinfection syndrome, a life-threatening dissemi-
nated infection with a mortality rate over 50% despite
treatment [7].
A prior cost-effectiveness analysis found that pre-
sumptive treatment of immigrants with albendazole
could save lives and money; basing treatment de-
cisions on stool analysis was more expensive and less
effective than presumptive treatment [4]. This analysis
included various parasites, and found that both gains
in quality-adjusted life and economic benefits hinged
on the eradication of S. stercoralis, the organism re-
sponsible for the hyperinfection syndrome. The
analysis did not evaluate the practice of basing clinical
decisions on eosinophil counts and did not evaluate
alternative presumptive treatment modalities.
Ivermectin, a newer anti-parasitic agent, is more
effective against S. stercoralis than albendazole and is
administered as a single dose, but is narrower in its
spectrum of activity and considerably more expensive
than albendazole. Therefore, there is uncertainty sur-
rounding the optimal medication for the presumptive
treatment of this parasite in immigrants, especially
among those at high risk for strongyloidiasis.
We compare the cost-effectiveness of treatment
with single-dose ivermectin with two commonly em-
ployed regimens of albendazole as well as treatment
based on eosinophil counts. Immigrants are often
screened for anaemia using a complete blood count
(CBC) with differential. Information on a patient’s
eosinophil count is, therefore, available to clinicians
at no cost ; thus, screening for eosinophilia is intuit-
ively cost-effective. We, therefore, also report the
cost-effectiveness of treating immigrants with known
eosinophilia (defined as an absolute eosinophil count
>500 or percentage of total leukocytes >5%), and
provide a comparison to the other treatment strat-
egies mentioned above.
METHODS
Our study design adhered to the recommendations of
the Panel on Cost-Effectiveness in Health and
Medicine [8, 9]. All relevant societal costs were in-
cluded, and future costs were discounted at a rate of
3%. Since there is considerable uncertainty sur-
rounding the real world value for various parameters
used in the analysis, we employed various sensitivity
analysis techniques. The sensitivity analysis informs
the reader of the effect incorrect estimates of a vari-
able or differences in infection rates between various
immigrant groups might have on the incremental
cost-effectiveness ratios. For simplicity, all foreign-
born persons are referred to as immigrants, regardless
of documentation or worker status.
Prevalence
The prevalence of parasitosis among immigrants to
the United States was obtained from the medical
literature and from refugee and immigrant health
clinics [10–16]. The prevalence data we used were
based on a standard single stool ova and parasite
examination, which has an average test sensitivity
value of approximately 25% [17, 18]. The adjusted
prevalence of S. stercoralis among immigrants was
then calculated by dividing the proportionate preva-
lence value for a given immigrant population by the
test sensitivity.
Morbidity and mortality
To calculate life expectancy for immigrants, we first
generated abridged life tables using data from the
National Centre for Health Statistics for year 2000.
Because immigrants are born outside the United
States by definition, these life tables reflect life ex-
pectancy starting at age 1 year.
Deaths due to S. stercoralis [International
Classification of Disease, 9th Revision (ICD-9) code
127.2] were obtained from the 1979–1998 combined
mortality data file for California and New York – two
states with large immigrant populations in which S.
stercoralis is not endemic [19]. The probability of
mortality was calculated as follows:
D=(P  I),
where D=deaths due to S. stercoralis, I=the 1990
immigrant population of these states, and P=the
overall prevalence of parasitosis in immigrants [20]. In
this case, the 1990 immigrant population was used
because it fell approximately mid-point between in-
itial and final years of the death data file.
The number of hospitalizations due to S. stercoralis
was obtained using 1996–2000 data from the State-
wide Planning and Regional Cooperative System
(SPARCS), a dataset containing billing, demographic,
and diagnosis data for all civilian hospitalizations
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in New York State [21]. Hospitalization rates were
calculated as follows:
H=(I  P),
where H is the average annual number of hospital-
izations for S. stercoralis from 1996 to 2000, I is the
1998 immigrant population, and P is the prevalence of
S. stercoralis.
The number of outpatient visits to health-care
providers was calculated from Medicaid claims data
from 1992 to 1996 [22]. More recent data were un-
available due to a 1996 federal law preventing recent
immigrants from using most Medicaid services. The
mean annual number of outpatient visits was divided
by the proportion of immigrants receiving Medicaid
throughout those years.
Estimates of the Health-related quality of life
(HRQL) scores for various health states were derived
using the Health Utilities Index 2 (HUI-2), which is a
multi-attribute health status classification system used
to translate dimensions of a disease into a quality
adjusted life years (QALY)-compatible HRQL score
[23]. Domains include sensation, mobility, cognitive
function, self-care, and pain among others. Inputs
were obtained by asking two infectious disease experts
familiar with S. stercoralis to rate each scale.
Efficacy
Most efficacy trials of anti-parasitic agents are con-
ducted overseas and are complicated by the potential
for re-infection and the use of insensitive tests to
identify infection. Determination of the sensitivity of
eosinophilia for S. stercoralis infection is limited by
the lack of a gold standard comparator and a paucity
of studies. Finally, since eosinophilia occurs in the
presence of many parasitic infections (as well as other
medical conditions), the specificity of the test is de-
pendent on the prevalence of other conditions in a
given cohort. We, therefore, used mean values for
sensitivity and specificity for eosinophilia and efficacy
estimates for albendazole and ivermectin from the
medical literature and tested these in a broad sensi-
tivity analyses (see Table 1) [24–31].
Table 1. Selected parameters included in the decision analysis model*
Base High Low Ref.
Cost per patient ($2000)
Mean cost of hospitalization# $13 109 $30 400 $8000 [21, 34]
Cost of outpatient visit# $75 $130 $20 [33]
Cost of burial $7020 $10 000 $3000 [35]
Cost of 200 mg b.i.d albendazole (5 days) $13.24 $15.00 $2.00$ [32]
Cost of 200 mg b.i.d. albendazole (3 days) $7.94 $9.00 $1.33$ [32]
Cost of 12 mg ivermectin once $21.76 $22.00 $5$ [32]
Probabilities
Discount rate 0.03 0.06 0.0 [8]
Probability of infection 0.10 0.02 0.2 [10–18]
Effectiveness of albendazole (3 days) 60% 80% 40% [25–28]
Effectiveness of albendazole (5 days) 80% 90% 60% [25, 26]
Effectiveness of ivermectin 92% 99% 80% [25, 26]
Sensitivity of eosinophilia 80% 90% 40% [27, 28]
Specificity of eosinophilia 25% 50% 2% [27, 28]
Probability of mortality# 6.48r10x5 0.00006 6.48r10x5 [19, 20]
Probability of hospitalization#· 0.000023 0.0002 0.000023 [20, 21]
Probability of outpatient visit# 0.000425 0.004 0.000425 [22]
Health-related quality of life (HRQL)
Well 1 1 0.84 [23]
Infected, ambulatory 0.919 1 0.7 [23]
Infected, hospitalized 0.799 0.9 0.5 [23]
* For a full list of parameters, including age-specific mortality rates, visit http://www.pceo.org/parasitecea.html.
# Among infected persons.
$ Used to determine threshold cost. Medications are available overseas for less than low value.
· Annual risk among infected persons.
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Costs
The cost of ivermectin was based on a single dose of
12 mg (approximately 200 mg/kg for a 60 kg adult),
and the cost of albendazole was based on a twice-daily
dose of 200 mg for either 3 or 5 days. Each cost was
obtained from the 2000 Red Book, which reports
average wholesale prices for medications [32]. The
median cost of medical visits were estimated using
2000 data from the Medical Care Expenditure Panel
Survey (MEPS), an annual survey of approximately
40 000 households that is representative of the US
population as a whole. We used the median cost
since data for S. stercoralis were not available and
since a medical visit for this condition is likely
to fall in the middle range of duration. Details of
the survey, including imputation methods, are avail-
able from the Agency for Health Research and
Quality [33].
The median cost of a hospitalization for S. ster-
coralis was obtained using charge data from SPARCS
for admissions with ICD-9 code 127.2 listed as a pri-
mary diagnosis [21]. These figures were then adjusted
using the cost-to-charge ratio for ‘other infectious
and parasitic diseases’ (Diagnosis-Related Group
423, which includes helmenthiasis), which was derived
from the Centers for Medicare and Medicaid Services
(CMS) [34]. This cost-to-charge ratio was calculated
by dividing the amount reimbursed by CMS by
the total charges to CMS. Burial costs were added
for all deaths, regardless of cause, since burial costs
associated with premature death were expected to
be relevant after discounting future costs [35]. The
HUI-2 does not include costs due to lost productivity ;
however, we chose to exclude these costs because we
felt that they would be small relative to the actual cost
of care.
Decision analysis model
We developed a Markov model using DATA pro-
fessional (version 4.0, TreeAge Software, Williams-
town, MA, USA) that compared: (1) treating all
immigrants with 200 mg albendazole twice a day for
either 3 days or 5 days, (2) treating all immigrants
with 12 mg ivermectin in a single dose (approxi-
mately 200 mg/kg for a 60 kg adult), (3) treating only
those immigrants with documented eosinophilia with
12 mg ivermectin, and (4) watchful waiting. In our
model, subjects are exposed to the annual age-specific
probability of death for immigrants due to all causes ;
the crude mortality rate for S. stercoralis infection
was subtracted for uninfected or successfully treated
subjects. Each surviving subject is assigned a dis-
counted HRQL value or cost for each year of life.
Burial costs are incurred whenever subjects die. All
assumptions of the analysis are listed in Table 2 and
all parameter values are listed in Table 1.
In the model, patients are assigned to a state of
being either infected with S. stercoralis or uninfected.
In treatment arms, the probability of infection is
equal to the product of the parasitic prevalence and
the efficacy of the medication administered. In the
eosinophilia arm, subjects are allocated to receive
treatment or no treatment by infection status using
the prevalence, sensitivity, and specificity of the test.
Table 2. Assumptions and issues in deriving parameter estimates
. The 1990 immigrant population is equal to the midpoint 1979–1998 population
. It was necessary to aggregate mortality data for S. stercoralis over many years to obtain a large number of deaths
in the numerator of mortality ratios
. Vital statistics and hospitalization data correctly tabulate mortality and hospitalization rates due to S. stercoralis
. Most cases are not likely to be identified, resulting in undercounts of deaths and hospitalizations. This assumption
was tested in a broad sensitivity analysis
. The exclusion of parasites other than S. stercoralis will not substantially alter cost-effectiveness ratios in populations
at known risk of this parasite
. We examined only costs and benefits associated with screening and treating S. stercoralis. Unlike albendazole,
ivermectin does not treat hookworm, G. lamblia, O. vivirini, or T. solum. However, the mortality due to G. lamblia is
extremely low, O. vivirini is rare, and considerable debate exists over whether albendazole would produce benefits for
persons infected with T. solum
. The HRQL of uninfected immigrants is 1.0
. We tested this assumption in a sensitivity analysis varying from the mean HRQL of native-born persons to 1.0
. Clinicians will use 12 mg ivermectin to treat patients with eosinophilia among populations at risk for S. stercoralis
. S. stercoralis is the most dangerous parasite and ivermectin is the most effective medication. Some infectious
disease specialists may opt to use a higher dose and spaced dosing to maximize efficacy, which would decrease the
cost-effectiveness of this option
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The variables used in our analyses were subjected to
a Monte Carlo simulation and to a series of one-way
and two-way sensitivity analyses. In a one-way
analysis, all variables are held constant but one. In a
Monte Carlo simulation, values for all variables are
sampled from a statistical distribution. In our Monte
Carlo simulation, we used a triangular distribution
[36]. In this distribution, the base-case estimate is
entered as the most likely value, and the likelihood
of values between this value and the high and low value
are linearly interpolated.
RESULTS
Table 3 presents the results of the cost-effectiveness
analysis at a 2, 10, and 20% prevalence of S. stercor-
alis infection. When the prevalence of S. stercoralis is
10% (a rate commonly seen in mixed refugee screen-
ing settings), presumptive treatment with 200 mg
albendazole, twice a day over 3 days, was associated
with an incremental cost-effectiveness ratio of $314
per QALY gained relative to watchful waiting. The
presumptive treatment of immigrants at risk of para-
sitosis with 5 days of albendazole may be desired
to ensure better coverage of S. stercoralis as well as
other parasitic infections such as Giardia lamblia.
This option is associated with an incremental cost-
effectiveness ratio of $632 relative to 3 days of alben-
dazole and $393 relative to watchful waiting. Optimal
coverage of S. stercoralis can be achieved with iver-
mectin. Presumptive treatment with 12 mg ivermectin
in a single dose was associated with a cost of $1700
per QALY gained relative to treatment with 5 days
of albendazole and $564 per QALY gained relative
to watchful waiting. Regardless of the prevalence,
the strategy of basing treatment on previously
known eosinophil results (i.e. excluding the cost of
a complete blood count with differential) was both
more expensive and less effective than other options
(dominated).
The Figure presents mean effectiveness and in-
cremental cost-effectiveness ratios of the treatment
strategies at various prevalence ratios of S. stercoralis
infection. Presumptive treatment of immigrants with
ivermectin increases incremental cost-effectiveness
alongside prevalence ratios, with maximal cost-effec-
tiveness when prevalence ratios are greater than
10–12%. Over the range of prevalence values ex-
amined, none of the presumptive treatment strategies
was clearly preferred over another.
All variables listed in Table 1 were tested in one-
way and Monte Carlo sensitivity analyses. Changes in
Table 3. Cost, incremental cost, effectiveness, incremental effectiveness, and incremental cost-effectiveness per











Watchful waiting $1666 — 25.91 QALYs — — —
Albendazole (3 days) $1674 $8 25.92 QALYs 0.0050 QALYs $1584 $1584
Albendazole (5 days) $1680 $5 25.92 QALYs 0.0017 QALYs $3175 $1982
Eosinophil screening $1684 $4 25.92 QALYs (0.0006 QALYs) Dominated# Dominated#
Ivermectin (once) $1688 $9 25.92 QALYs 0.0010 QALYs $8514 $2834
10% Prevalence
Watchful waiting $1666 — 25.88 QALYs — — —
Albendazole (3 days) $1674 $8 25.90 QALYs 0.0250 QALYs $314 $314
Albendazole (5 days) $1680 $5 25.91 QALYs 0.0083 QALYs $632 $393
Eosinophil screening $1684 $4 25.91 QALYs (0.0029 QALYs) Dominated# Dominated#
Ivermectin (once) $1688 $9 25.92 QALYs 0.0050 QALYs $1700 $564
20% Prevalence
Watchful waiting $1667 — 25.84 QALYs — — —
Albendazole (3 days) $1674 $8 25.89 QALYs 0.0500 QALYs $155 $155
Albendazole (5 days) $1680 $5 25.90 QALYs 0.0167 QALYs $314 $195
Eosinophil screening $1684 $4 25.90 QALYs (0.0057 QALYs) Dominated# Dominated#
Ivermectin (once) $1688 $8 25.91 QALYs 0.0100 QALYs $848 $280
* Relative to watchful waiting.
# Dominated strategies are both more expensive and less effective than others.
CEA of strongyloidiasis 1059
the efficacy of the regimens over plausible values
exerted only a moderate effect on the relative ranking
of each regimen, and changes in other variables had
no substantive effect on strategy rankings. Notable
analyses that exerted little effect on the model include
the discount rate, the cost and probability of medical
events, and state-specific HRQL scores. In Monte
Carlo analyses, all three presumptive treatment
strategies overlapped considerably. Any given strat-
egy exceeded $50 000 in less than 1% of all trials.
DISCUSSION
In our analysis we found that ivermectin was a more
effective strategy, but was also an incrementally more
expensive (per QALY gained) than albendazole for
the treatment of S. stercoralis infections in new im-
migrants to the United States. The additional expense
of ivermectin was $1700 per QALY gained, a very
small cost relative to most other medical interven-
tions in the United States. Across prevalence ratios
commonly seen in immigrant groups, the cost of pre-
sumptive treatment is significantly less than the cost
of treatment of essential hypertension in 20-year-old
males vs. no treatment, or the nicotine patch for 25-
year-old smokers vs. no treatment [37]. While the
incremental cost-effectiveness of ivermectin was de-
pendent upon the underlying prevalence of S. ster-
coralis infection, no one strategy clearly dominated
the other.
In evaluating the use of eosinophil counts to guide
presumptive treatment, we used a high estimate of
test sensitivity, a generous specificity, and did not
include the cost of a CBC with differential in the
analysis. All of this increases the likelihood of a find-
ing in favour of incorporating eosinophilia data;
nonetheless the strategy was dominated. Though the
positive predictive value of eosinophilia increases with
increasing parasite prevalence, this strategy becomes
more costly and less effective than the other options as
prevalence increases. This is attributable to increasing
false-negative test results. While the test has a higher
positive predictive value when all intestinal parasites
that cause eosinophilia are considered together, other
parasites are infrequently fatal and generate fewer
costs than S. stercoralis. It is, therefore, unlikely that
adding other intestinal helminths to the model (with
concomitant improvements in specificity) would
greatly improve the incremental cost-effectiveness of
this option.
The prevalence of S. stercoralis varies considerably
by region of the world and the subpopulation sam-
pled. For example, Gyorkos et al. [38] conducted a
serosurvey for S. stercoralis among Southeast Asians
immigrating to Canada and reported that Cambo-
dians had a seroprevalence of 76.6%, Laotians had a
seroprevalence of 55.6%, and Vietnamese had a
seroprevalence of 11.8%. Serology indicates both
active and previous infections and may produce an
overestimate of the prevalence of S. stercoralis.
Nonetheless, these numbers underscore the hetero-
geneity of infection rates among different groups;
predominately high-risk refugees screened with 1–3
stool ova and parasite examinations in Texas and
Minnesota have an average uncorrected infection rate
of 1.8–4% (or approximately 3–12% after correction
for the sensitivity of the stool ova and parasite
examination) [39, 40]. We demonstrate that pre-
sumptive treatment is cost-effective across a wide
range of prevalence values. Clinics that treat refugees
and immigrants may wish to use our data to tailor
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Prevalence of S. stercoralis
(a)
(b)
Fig. Effectiveness and incremental cost-effectiveness of the
strategies under evaluation. Ivermectin is the most effective
strategy across the prevalence ratios of S. stercoralis (a).
–&–, Ivermectin (1 day) ; –‚–, albendazole (5 days) ; –m–,
albendazole (3 days) ; –$–, eosinophil ; –––, nothing.
However, it is more expensive than other strategies (b).
Dominated options are not shown in panel (b).
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in the population they treat, the mix of parasites in the
population they treat, and budgetary concerns.
For instance, albendazole has a broader spectrum
of action and includes activity against hookworm and
G. lamblia, as well as certain flatworms. Both iver-
mectin and albendazole provide coverage of other
infections as well, including Ascaris lubricoides,
Trichuris trichiura, and certain forms of filariasis [41].
While estimating the morbidity or costs associated
with administering albendazole for some of these
organisms is limited by inadequate data, short-term
clinical and public health benefits may be realized
from the presumptive treatment of immigrant and
refugee populations using broad spectrum anti-
parasitic medications. However, the elimination of
S. stercoralis should be prioritized in populations
in whom this parasite is prevalent given its potential
for life-threatening illness and capacity for auto-
infection.
Our inability to capture the costs and benefits of
presumptively treating these other parasites is a limi-
tation of this study. Including them would probably
improve the incremental cost-effectiveness of 5 days
of albendazole relative to 3 days of albendazole
treatment or ivermectin. It would also slightly im-
prove the incremental cost-effectiveness of eosinophil
screening. Another limitation is the use of billing and
vital-statistics data to capture the morbidity and
mortality associated with S. stercoralis. Contributing
to misclassification bias in datasets is clinicians’ un-
familiarity with the disease and the lack of a sensitive
diagnostic test. Even tuberculosis, a condition that
is probably more familiar to clinicians, is correctly
classified on death certificates just 34% of the time
[42]. Misclassification bias probably results in an
underestimate of medical visits and deaths due to this
parasite but would not substantially affect the rank
order of the modalities.
Finally, we were unable to evaluate all possible
screening and treatment strategies. Strategies for
selecting persons at risk for S. stercoralis include stool
ova and parasite screening, obtaining eosinophil
counts [43], asking patients about rural or urban
residence [44], screening for the presence of asthma-
like respiratory symptoms [45] and serological
screening tests [46]. While stool screening examina-
tions [4] and treatment contingent on known eosino-
phil counts are more expensive and less effective than
presumptive treatment, there are insufficient data to
evaluate the other options. Serological screening is
much more sensitive than stool screening, however
the cost and positive predictive value of this option
render it an unlikely addition to the arsenal of cost-
effective preventive modalities. One option in need of
evaluation is screening based on urban or rural resi-
dence in the country of origin. Knowledge of the prior
probability of infection could greatly reduce the
number of uninfected persons who would otherwise
receive treatment.
Alternative treatment options exist as well. For in-
stance, ivermectin has been combined with albenda-
zole in some international studies [47, 48]. We did not
evaluate this approach as a policy due to concerns
surrounding the possibility of drug interactions.
It is also prudent to limit presumptive treatment to
those for whom the drugs have demonstrated safety.
Ivermectin and albendazole are pregnancy category C
drugs [30, 31].
The present analysis improves upon an earlier study
[4]. In addition to improving mortality and hospital-
ization rate estimates by using multiple years of data,
it uses a Markov model and includes additional pre-
ventive strategies. Using a deterministic model and
discounted lifetime probabilities of hospitalization
and death, that study biased all variables against
presumptive treatment, evaluated multiple parasites,
and found cost savings associated with presumptive
treatment with 5 days of albendazole. The cost
savings realized by that study were attributable to
slightly higher hospitalization and mortality estimates
for S. stercoralis (due to random error associated
with the use of a single year of data) and the inclusion
of four parasites rather than one. Though the present
analysis demonstrates that treatment may be associ-
ated with costs, it should be emphasized that the num-
ber of deaths and hospitalizations in the real world
are likely to be substantially higher than reported in
national datasets. Therefore, the costs averted by
treatment are likely to be substantially higher.
Immigrants from Eastern Europe, Asia, Africa,
Latin America, and the Middle East are all at risk of
parasitosis, but there is considerable variability even
within these groups. The ideal management of para-
sitic infections in immigrant populations might
consider the population’s risk of infection with S. ster-
coralis relative to other parasites. Many institutions,
such as most federal refugee health clinics, have these
data. By combining our analysis with nation-specific
data on the prevalence of S. stercoralis infections,
providers should be able to maximize the quality and
quantity of life of their immigrant populations within
their own budgetary constraints.
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